Stephanie J. Lee Publications

For a complete list of publications, please visit Dr. Lee's NCBI Bibliography.

Papers since 2020 from the Chronic GVHD Consortium (from a total of 576)

Clinical trials

  1. Pidala J, Jaglowski S, Im A, Chen G, Onstad L, Storer B, Kurukulasuriya C, Lee SJ. Carfilzomib for treatment of refractory chronic graft-vs.-host disease: A Chronic GVHD Consortium pilot phase II trial. Biol Blood Marrow Transplant 2020; 26: 278-284.
  2. Pidala J, Bhatt VR, Hamilton B, Pusic I, Wood WA, Onstad L, Hall A, Storer B, Lee SJ. Ixazomib for treatment of refractory chronic graft vs. host disease: A Chronic GVHD Consortium phase II trial: Ixazomib for chronic GVHD treatment; Biol Blood Marrow Transplant 2020; 26: 1612-1619.
  3. Sun YC, Inamoto Y, Wang RK, Lee SJ, Hung KF, Shen TT. The disposable bandage soft contact lenses therapy and anterior segment optical coherence tomography for management of ocular graft-versus-host disease. BMT Ophthal 2021; 21: 271.
  4. Lazaryan A, Lee S, Arora M, Kim J, Betts B, Khimani F, Nishihori T, Bejanyan, Liu H, Kharfan-Dabaja M, Locke F, Gonzalez R, Jain M, Davila M, Perez L, Mishra A, Perez AP, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand R, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. Phase II multicenter trial of ofatumumab and prednisone as initial therapy of chronic graft-versus-host disease. Blood Adv 2021; 11: 259-269.
  5. Williams KM, Pavletic SZ, Lee SJ, Martin PJ, Farthing DE, Hakim FT, Rose J, Manning-Geist BL, Gea-Banacloche JC, Comis LE, Cowen EW, Justus DG, Baird K, Cheng GS, Avila D, Steinberg SM, Mitchell SA, Gress RE. Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplantation and investigation into bronchiolitis obliterans syndrome pathogenesis.  Transplant Cell Ther 2022; 28: 264e1-e9 .
  6. Rodriguez-Arboli E, Lee CJ, Caballero-Velazquez T, Martinez C, Garcia-Calderon C, Jimenez-Leon MR, Bermudez-Rodriguez MA, Lopez-Corral L, Triguero A, Onstad L, Horwitz ME, Sarantopoulos S, Lee SJ, Perez-Simon JA. Targeting hedgehog signaling with glasdegib in patients with refractory sclerotic chronic graft-vs.-host disease: a report of two phase I/II trials. Clin Cancer Res 2023; 29: 4057-4067.
  7. Bhatt VR, Shostrom VK, Choe HK, Hamilton BK, Gundabolu K, Maness LJ, Kumar V, Mahato RI, Smith LM, Nishihori T, Lee SJ. A multicenter phase II trial of ruxolitinib for treatment of corticosteroid refractory sclerotic chronic graft-versus-host disease. J Clin Oncol 2024; 42: 3977-3985.
  8. Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermudez A, Kim I, Socie G, Chhabra S, Radojcic V, O’Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL. Axatilimab in recurrent or refractory chronic graft-versus-host disease. New Engl J Med 2024, 39: 1002-1014.

 

Organ-specific studies

  1. Johnson LB, Oh U, Rothen M, Sroussi HY, Dean DR, Lloid CM, Cintron K, Lee SJ, Cutler CS, Treister NS. A review of oral chronic graft-versus-host disease: considerations for dental hygiene practice. J Dent Hyg 2022, 96: 6-17.
  2. DePriest BP, Li H, Bidgoli A, Onstad L, Couriel D, Lee SJ, Paczesny S. Regenerating islet-derived protein 3-a is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease. Blood Adv 2022; 6: 2981-2986.
  3. Baumrin E, Baker LX, Byrne M, Martin PJ, Flowers ME, Onstad L, El-Jurdi N, Chen H, Beeghly-Fadiel A, Lee SJ, Tkaczyk ER. Prognostic value of cutaneous disease severity estimated on survival outcomes in patients with chronic graft-vs-host disease. JAMA Derm 2023; 159: 393-402.
  4. Baumrin E, Shin DB, Mitra N, Pidala J, El Jurdi N, Lee SJ, Loren AW, Gelfand JM. Patient-reported outcomes and mortality in cutaneous chronic graft-vs-host disease. JAMA Dermatol 2024; 160: 393-401.
  5. Te C, Elahi T, Samples K, Onstad L, Lee SJ. Serositis associated with chronic graft-versus-host disease. Transplant Cell Ther 2025, 31: 902.e1-e6.

 

Biomarkers

  1. Inamoto Y, Martin P, Lee SJ, Momin AA, Tabellini L, Onstad LE, Pidala J, Flowers MED, Lawler RL, Katayama H, Hanash S, Hansen JA. Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation Blood Adv 2020; 4: 2409-2417.
  2. Inamoto Y, Martin PJ, Onstad LE, Cheng GS, Williams KM, Pusic I, Ho VT, Arora M, Pidala J, Flowers MED, Gooley TA, Lawler RL, Hansen JA, Lee SJ. Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Transplant Cell Ther 2021; 27: 759e1-759e8.
  3. Boiko JR, Ensbey KS, Waltner OG, Bhise SS, MacDonald KPA, Blazar BR, Hall AM, Gooley TA, Jenkins IC, Minnie SA, Lee SJ, Furlan SN, Hill GR. Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease. Blood 2025; 2214-2228.
  4. El Jurdi N, Hamilton BK, Pidala JA, Onstad L, Mun C, Jain S, Lee SJ. Longitudinal tear cytokine biomarkers: an analysis from the Close Assessment and Testing for Chronic graft-versus-host disease (CATCH) protocol. Transplant Cell Ther 2025, 31: 226e1-e9.
  5. Rashidi A, Pidala J, Hamilton BK, Pavletic SZ, Kim K, Zevin A, Mays JW, Lee SJ. Oral and gut microbiome alterations in oral chronic graft-verus-host disease: results from Close Assessment and Testing for Chronic GVHD (CATCH study). Clin Cancer Res 2024; 30: 4240-4250.
  6. El Jurdi N, Hamilton BK, Pidala JA, Onstad L, Mun C, Jain S, Lee SJ. Longitudinal tear cytokine biomarkers: an analysis from the Close Assessment and Testing for chronic graft-vs.-host disease (CATCH) protocol, Transplant Cell Ther 2025; 226.e1-e9.
  7. Farhadfar N, El Jurdi N, Baker K, Ghosh S, Bat-Erdene M, Desatnik G, Williams L, Tkaczyk ER, Lee SJ. Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease. Blood Adv 2025; in press.

 

NIH Consensus Criteria

  1. Inamoto Y, Lee SJ, Onstad LE, Flowers MED, Hamilton BK, Jagasia MH, Martin PJ, Pavletic SZ, Pidala JA, Pusic I, Vogelsang GB, Wolff D, Carpenter PA. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Adv 2020; 14: 40-46.
  2. Pidala JA, Onstad L, Baumrin E, Carpenter PA, Cutler C, Arai S, Kitko CL, Chen GL, Lee SJ. Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation. Blood Adv 2024; 8: 4651-4657.
  3. Lee SJ, Williams KM, Sarantopoulos S, Kitko CL, Cutler C, Pidala J, Hill GR, DeFilipp Z, Greinix HT, Wolff D, Paczesny S, Cuvelier GDE, Schultz KR, Pavletic SZ. NIH chronic graft-versus-host disease consensus conference 2025 update. Transplant Cell Ther 2025, 31:678.e1-e16.
  4. Wolff D, Cutler C, Mercep I, Jaki T, Robertson DS, Schultz KR, Lee SJ, Martin PJ, Pavletic SZ. Towards better and more effective clinical trials for chronic graft-versus-host disease. Transplant Cell Ther 2025, in press.
  5. Markova A, Lee SJ, Baumrin E, Rosenstein RK, Tkaczyk ER, Holtzman N, Lehman JS, Schultz KR, Martin P, Pusic I, Harris A, Ponce DM, Goklemez S, Paczesny S, Stockmann C, Pinal-Fernandez I, El Jurdi N, Pavletic SZ, Cowen EW. Towards better response assessment of cutaneous chronic graft-versus-host disease: a report from the National Institutes of Health Consensus Project Task Force. Transplant Cell Ther 2026, in press.

 

Outcomes studies

  1. Hamilton BK, Storer BE, Wood WA, Pidala JA, Cutler CS, Martin PJ, Chen G, Flowers ME, Lee SJ. Disability related to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2020; 26: 772-777.
  2. DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, Arora M, Cutler CS, Flowers MED, Kitko CL, Chen GL, Lee SJ, Hamilton BK. Nonrelapse mortality among patients diagnosed with chronic GVHD: An updated analysis from the Chronic GVHD Consortium. Blood Adv 2021; 5: 4278-4282
  3. Pidala J, Onstad L, Martin P, Hamilton B, Cutler C, Kitko C, Carpenter P, Chen G, Arora M, Flowers M, Arai S, Alousi A, White J, Jacobsohn D, Pusic I, Lee SJ. Initial therapy of chronic graft-vs.-host disease: Analysis of practice variation and failure-free survival. Blood Adv 2021; 5: 4549-4559
  4. Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, Cutler C, Hamilton BK, Lee SJ, Arora M. Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease. Haematologica 2023; 108: 483-489.
  5. Manjappa S, Phi HQ, Lee LW, Onstad L, Gill DB, Connelly-Smith L, Krakow EF, Flowers ME, Carpenter PA, Hill JA, Lee SJ. Humoral and cellular immune response to Covid-19 vaccination in patients with chronic graft-versus-host disease on immunosuppression. Transplant Cell Ther 2022, 11: 784.e1-784.e9.
  6. Rashid N, Arora M, El Jurdi N, Onstad L, Pidala JA, Flowers MED, Lee SJ. Frailty in chronic graft-versus-host disease. Transplant Cell Ther 2023; 29: 367-374.
  7. Pidala J, Carpenter PA, Onstad L, Pavletic SZ, Hamilton BK, Chen GL, Farhadfar N, Hall M, Lee SJ. Study Protocol: Close Assessment and Testing for chronic graft-vs.-host disease (CATCH). PLOSOne 2024; 19:e0298026.
  8. Hamilton BK, Onstad L, Carpenter PA, Pidala JA, El Jurdi N, Farhadfar N, Kitko CL, Lee CJ, Mehta R, Chen GL, Cutler C, Lee SJ. Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in chronic graft-versus-host disease. Contemp Clin Trials 2024; 145: 107637.
  9. Carpenter PA, Gooley TA, Boiko J, Lee CJ, Burroughs LM, Mehta R, Salit RB, Bhatt NS, Krakow E, Dahlberg AE, Yeh AC, Summers CN, Ueda Oshima M, Petersdorf EW, Vo P, Connelly-Smith L, Lee SJ. Decreasing chronic graft-versus-host disease rates in all populations. Blood Adv 2024; 8: 5829-5837.
  10. Lee SJ, Zeiser R. FDA-approved therapies for chronic GVHD. Blood 2025; 145: 795-800.
  11. Pidala J, Onstad L, Carpenter P, Hamilton BK, Kitko CL, Juckett M, Cutler C, Lee SJ. Longitudinal study of late acute and chronic GVHD after allogeneic hematopoietic cell transplantation: A long-term follow up study from the Chronic GVHD consortium. Transplant Cell Ther 2025, in press.
  12. Ardila V, Onstad L, Carpenter P, Pidala J, Kitko C, El Jurdi N, Lee SJ, Hamilton BK. Obesity associations with chronic graft-versus-host disease. Transplant Cell Ther 2025, in press.
  13. Babu V, Shin DB, Onstad L, Pidala JA, Chen G, Lee CJ, Kitko CL, Carpenter P, Cutler C, El Jurdi N, Loren AW, Gelfand JM, Lee SJ, Baumrin E. Discordant perceptions of treatment response between clinicians and patients with cutaneous chronic GVHD. JAMA Derm 2026, in press.

 

Quality of life

  1. The C, Onstad L, Lee SJ. Reliability and validity of the modified 7-day Lee Chronic Graft-versus-Host Disease Symptom Scale. Biol Blood Marrow Transplant 2020; 26: 562-567,
  2. Baumrin E, Pidala J, Mitchell SA, Onstad L, Lee SJ. Development of the Lee Symptom Scale – skin sclerosis (LSS-Scl) for chronic GVHD-associated sclerosis. Blood 2025; 145: 1321-1332.